Drug Resistance and Novel Therapies in Cancers

Wang, Zhixiang

doi:10.3390/cancers12102929

Cited by 2 publications

(2 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although many chemotherapeutics have been clinically employed to avoid the recurrence of malignancy after surgery, acquired chemotherapy resistance remains the biggest challenge to the successful treatment of patients with lung cancer [ 39 , 40 ].…”

Section: Resultsmentioning

confidence: 99%

Tin Mesoporphyrin Selectively Reduces Non-Small-Cell Lung Cancer Cell Line A549 Proliferation by Interfering with Heme Oxygenase and Glutathione Systems

et al. 2021

View full text Add to dashboard Cite

In order to maintain redox homeostasis, non-small-cell lung cancer (NSCLC) increases the activation of many antioxidant systems, including the heme-oxygenase (HO) system. The overexpression of HO-1 has been often associated with chemoresistance and tumor aggressiveness. Our results clearly showed an overexpression of the HO-1 protein in A549 NSCLC cell lines compared to that in non-cancerous cells. Thus, we hypothesized that “off-label” use of tin mesoporphyrin, a well-known HO activity inhibitor clinically used for neonatal hyperbilirubinemia, has potential use as an anti-cancer agent. The pharmacological inhibition of HO activity caused a reduction in cell proliferation and migration of A549. SnMP treatment caused an increase in oxidative stress, as demonstrated by the upregulation of reactive oxygen species (ROS) and the depletion of glutathione (GSH) content. To support these data, Western blot analysis was performed to analyze glucose-6-phosphate dehydrogenase (G6PD), TP53-induced glycolysis and the apoptosis regulator (TIGAR), and the glutamate cysteine ligase catalytic (GCLC) subunit, as they represent the main regulators of the pentose phosphate pathway (PPP) and glutathione synthesis, respectively. NCI-H292, a subtype of the NSCLC cell line, did not respond to SnMP treatment, possibly due to low basal levels of HO-1, suggesting a cellular-dependent antitumorigenic effect. Altogether, our results suggest HO activity inhibition may represent a potential target for selective chemotherapy in lung cancer subtypes.

show abstract

Section: Resultsmentioning

confidence: 99%

Tin Mesoporphyrin Selectively Reduces Non-Small-Cell Lung Cancer Cell Line A549 Proliferation by Interfering with Heme Oxygenase and Glutathione Systems

et al. 2021

View full text Add to dashboard Cite

show abstract

“…With the identification of the right biomarker the cancer progression and effect of chemotherapeutic drugs can be evaluated in great detail [4]. Again, the presence of resistance to therapy, disease relapse, and individual differences continue to reduce the survival chances of cancer patients and makes the disease impossible to cure [5]. It is predicted that therapeutic response assessment, especially treatment response prediction, is valuable to guide treatment strategy determinations and provide responsive therapy for better survival [6].…”

Section: Introductionmentioning

confidence: 99%

Extracellular Vesicles as Biomarkers and Therapeutic Targets in Cancers

Barnie¹,

Afrifa²,

Ofori³

et al. 2022

Physiology

View full text Add to dashboard Cite

Extracellular vesicles refer to exosomes, apoptotic bodies, microvesicles and large oncosomes, which are membrane bound structures secreted by cells including cancer cells. The pathological role and translational potential of extracellular vesicles (EVs) in cancers are receiving research attention recently. The cargoes of cancer-derived EVs retain the molecular properties of their sources and cancer cells actively release EVs into body fluids that are easy to access. EVs released from cancer cells not only promote cancer progression through the delivery of cancer-associated molecules but also reflect alterations in the state of cancers during therapy. They are considered promising biomarkers for therapeutic response evaluation, especially resistance to therapy and diagnostics. This chapter discusses the various roles of extracellular vesicles in cancers and their potential as therapeutic targets.

show abstract

Drug Resistance and Novel Therapies in Cancers

Abstract: n/a

Cited by 2 publications

References 8 publications

Tin Mesoporphyrin Selectively Reduces Non-Small-Cell Lung Cancer Cell Line A549 Proliferation by Interfering with Heme Oxygenase and Glutathione Systems

Tin Mesoporphyrin Selectively Reduces Non-Small-Cell Lung Cancer Cell Line A549 Proliferation by Interfering with Heme Oxygenase and Glutathione Systems

Extracellular Vesicles as Biomarkers and Therapeutic Targets in Cancers

Contact Info

Product

Resources

About